Skip to main navigation
Skip to search
Skip to main content
Ariel University Home
Help & FAQ
English
עברית
العربية
Home
Profiles
Research units
Research output
Prizes
Activities
Search by expertise, name or affiliation
Future prospects and therapeutic potential of streptogramins
Ethan Rubinstein,
Nathan Keller
Research output
:
Contribution to journal
›
Article
›
peer-review
9
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Future prospects and therapeutic potential of streptogramins'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Antibacterial Agents
33%
Antibiotics
33%
Bacterial Infection
33%
Clinical Trials
33%
Endocarditis
33%
Enterococcus
66%
Enterococcus Faecium
33%
Epidemiological Trends
33%
Epidemiology
33%
Foreign Body
66%
Gram-positive Bacteria
33%
Gram-positive Cocci
33%
Gram-positive Pathogens
33%
Indwelling Medical Devices
33%
Infection Rate
33%
Infection Treatment
33%
Lactams
33%
Lincosamides
33%
Macrolides
66%
Methicillin
33%
Methicillin-resistant Coagulase-negative Staphylococci
33%
Multiresistant
66%
New Antibacterials
33%
Osteomyelitis
33%
Penicillin
33%
Semi-synthetic
33%
Sepsis
33%
Skin Tissue
33%
Soft Tissue Infection
33%
Staphylococcal Infections
33%
Staphylococcus Aureus
33%
Streptococcus Pneumoniae
33%
Streptogramins
100%
Susceptibility Pattern
33%
Teicoplanin
33%
Therapeutic Potential
100%
Tolerability
33%
Vancomycin
100%
Pharmacology, Toxicology and Pharmaceutical Science
Antibiotics
20%
Antiinfective Agent
40%
Bacterial Infection
20%
Clinical Trial
20%
Coagulase Negative Staphylococcus
20%
Endocarditis
20%
Enterococcus
40%
Enterococcus faecium
20%
Foreign Body
40%
Gram Positive Bacterium
20%
Gram Positive Cocci
20%
Infection
100%
Infectious Agent
20%
Lactam
20%
Lincosamide
20%
Macrolide
40%
Methicillin-Resistant Staphylococcus Aureus
40%
Meticillin
40%
Osteomyelitis
20%
Penicillin Derivative
20%
Sepsis
20%
Soft Tissue Infection
20%
Staphylococcal Infection
20%
Staphylococcus Aureus
20%
Streptococcus
40%
Streptogramin Derivative
100%
Teicoplanin
20%
Tolerability
20%
Vancomycin
60%